Coronary Artery Disease Clinical Trial
— FANTOM IIOfficial title:
Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold
Verified date | June 2024 |
Source | REVA Medical, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.
Status | Active, not recruiting |
Enrollment | 220 |
Est. completion date | September 2024 |
Est. primary completion date | August 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient has evidence of myocardial ischemia or a positive functional study - Target lesion has a visually estimated stenosis of =50% and <100% - Target lesion is located in a native coronary artery with average reference vessel diameter = 2.5mm and = 3.5mm - Lesion length = 20 mm by visual estimate (N/A for Cohort C) - Baseline TIMI flow = 2 Exclusion Criteria: - The patient has experienced an acute myocardial infarction (AMI: STEMI or NSTEMI) within 72 hours of the procedure and either CK-MB or Troponin has not returned to within 2X ULN. - Patient has a left ventricular ejection fraction < 40% - Patient has unprotected left main coronary disease with =50% stenosis - The target vessel is totally occluded (TIMI Flow 0 or 1) - Target lesion involves a bifurcation (a lesion with a side branch = 1.5 mm in diameter containing a = 50% stenosis). - Target lesion is located within a bypass graft - Target lesion has possible or definite thrombus |
Country | Name | City | State |
---|---|---|---|
Australia | The Prince Charles Hospital | Chermside | |
Australia | St Vincent's Hospital Sydney | Darlinghurst | |
Australia | Prince of Wales Hospital (Eastern Heart) | Randwick | |
Belgium | Cardiovascular Center Aalst | Aalst | |
Brazil | Instituto Dante Pazzanese de Cardiologia | Sao Paulo | |
Brazil | Albert Einstein Hospital | São Paulo | |
Denmark | Aarhus University Hospital (Skejby) | Aarhus | |
Denmark | Rigshospitalet | Copenhagen | |
Denmark | Odense University Hospital | Odense | |
France | institut Hospitalier J.Cartier | Massy | |
France | La Pitié-Salpétrière | Paris | |
France | Clinique Pasteur | Toulouse | |
France | Hôpital Rangueil | Toulouse | |
Germany | Am Urban Hospital, Berlin | Berlin | |
Germany | Friedrichshein Hospital, Berlin | Berlin | |
Germany | Klinikum Coburg | Coburg | |
Germany | St.- Johannes-Hospital Dortmund | Dortmund | |
Germany | Universitätsklinikum Erlangen | Erlangen | |
Germany | Elisabeth-Krankenhaus Essen | Essen | |
Germany | Universitätsklinikum Schleswig-Holstein | Kiel | |
Netherlands | Academic Medical Center Amsterdam | Amsterdam | |
Netherlands | Onze Lieve Vrouwe Gasthuis | Amsterdam | |
Netherlands | Erasmus Medical Center | Rotterdam | |
Netherlands | University Medical Center Utrecht | Utrecht | |
Poland | Krakowskie Centrum Kardiologii Inwazyjnej | Krakow | |
Poland | Szpital Uniwersytecki w Krakowie | Krakow | |
Poland | Szpital Kliniczny Przemienienia Panskiego UM w Poznaniu | Poznan | |
Poland | Oddzial Kardiologii Inwazyjnej I Katedra | Warszawa |
Lead Sponsor | Collaborator |
---|---|
REVA Medical, Inc. |
Australia, Belgium, Brazil, Denmark, France, Germany, Netherlands, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major Adverse Cardiac Events (MACE) - Cohorts A, B and C | Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB >5X ULN) (MI), and target lesion revascularization (TLR) | 6 months | |
Primary | Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C | Late Lumen Loss | 6 months | |
Secondary | Quantitative Coronary Angiography (QCA) derived parameters - Cohort B | Late Lumen Loss | 9 months | |
Secondary | Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C | Minimum Lumen Diameter (MLD) | 6 months | |
Secondary | Quantitative Coronary Angiography (QCA) derived parameters - Cohort B | Minimum Lumen Diameter (MLD) | 9 months | |
Secondary | Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C | % Diameter Stenosis | 6 months | |
Secondary | Quantitative Coronary Angiography (QCA) derived parameters - Cohort B | % Diameter Stenosis | 9 months | |
Secondary | Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C | Binary Restenosis | 6 months | |
Secondary | Quantitative Coronary Angiography (QCA) derived parameters - Cohort B | Binary Restenosis | 9 months | |
Secondary | Major Adverse Cardiac Events (MACE) - Cohorts A, B and C | Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB >5X ULN) (MI), and target lesion revascularization (TLR) | 12, 24, 36, 48 and 60 months | |
Secondary | Target Lesion Revascularization (TLR) - Cohorts A, B and C | Percentage of patients with TLR at each time point | 12, 24, 36, 48 and 60 months | |
Secondary | Target Vessel Revascularization (TVR) - Cohorts A, B and C | Percentage of patients with TVR at each time point | 12, 24, 36, 48 and 60 months | |
Secondary | Target Vessel Failure (TVF) - Cohorts A, B and C | Percentage of patients with TVF at each time point | 12, 24, 36, 48 and 60 months | |
Secondary | Acute Technical Success - Cohorts A, B and C | Successful acute delivery and deployment of the device | Day 0 | |
Secondary | Procedural Success - Cohorts A, B and C | Percentage of patients with angiographic success (final diameter stenosis <50% without occurrence of MACE) | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |